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the redesigned Foxp3 vaccine in the B16F10 melanoma 
model. Our results indicate that Foxp3 vaccination continu-
ously reduces Treg population in both the tumor site and the 
spleen. Surprisingly, Treg reduction was associated with a 
significant decrease in the frequency of MDSC, both in the 
spleen and in the tumor environment. Furthermore, Foxp3 
vaccination resulted in a significant reduction of arginase-
1(Arg-1)-induced nitric oxide synthase (iNOS), reactive 
oxygen species (ROS) and suppressed MDSC activity. 
Moreover, this concurrent depletion restored production of 
inflammatory cytokine IFN-γ and enhanced tumor-specific 
CTL response, which subsequently resulted in the reduction 
of tumor growth and the improved survival rate of vacci-
nated mice. In conclusion, our results revealed that Foxp3 
vaccine promotes an immune response against tumor by tar-
geting both Treg and MDSC, which could be exploited as a 
potential immunotherapy approach.
Keywords Regulatory T cells · Myeloid-derived 
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Abstract Regulatory T cells (Treg) and myeloid-derived 
suppressor cells (MDSC) are the two important and interac-
tive immunosuppressive components of the tumor micro-
environment that hamper anti-tumor immune responses. 
Therefore, targeting these two populations together might 
be beneficial for overcoming immune suppression in the 
tumor microenvironment. We have recently shown that 
prophylactic Foxp3 DNA/recombinant protein vaccine 
(Foxp3 vaccine) promotes immunity against Treg in tumor-
free conditions. In the present study, we investigated the 
immune modulatory effects of a prophylactic regimen of 
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Introduction
A growing body of evidence suggests that infiltrated immu-
nosuppressive cells in the tumor microenvironment, such 
as regulatory T cells (Treg) and myeloid-derived suppres-
sor cells (MDSC), hinder anti-tumor immune responses. In 
healthy individuals, Treg modulate many aspects of immune 
response, such as tolerance to self-antigen and prevention of 
autoimmune diseases [1]. These cells are a highly immuno-
suppressive subset of  CD4+ T cells characterized by expres-
sion of the master regulatory transcription factor Foxp3 
and high expression of IL-2 receptor α chain (CD25) [2]. 
In mice, according to the origin and suppressive function, 
Treg are classified into different subsets [3]. The pivotal role 
of Treg in the inhibition of anti-tumor immune responses is 
widely investigated. Treg are expanded at the tumor sites in 
various experimental models, and their presence is associ-
ated with higher tumor burden and poor prognosis, but their 
depletion promotes anti-tumor immune responses [4–6].
In addition to Treg, the failure of anti-tumor T-cell 
response also depends on the presence of MDSC, which 
increase in virtually all types of animal tumor models 
and human cancers. In mouse models of tumors, MDSC 
are characterized by the expression of granulocyte differ-
entiation marker 1 (Gr-1) and CD11b. According to the 
expression of Gr-1 subsets (Ly6G and Ly6C), MDSC are 
classified into granulocytic  (Ly6G+Ly6C−) and monocytic 
 (Ly6Glow/–Ly6C+) subpopulations; however, these pheno-
typic markers are not completely able to define these cells, 
but are functionally associated with immunosuppressive 
mechanisms, such as reactive oxygen species (ROS), induc-
ible nitric oxide synthase (iNOS), and arginase-1 (Arg-1) 
[7, 8].
Treg, together with MDSC, are the essential cells that 
contribute to the immunosuppressive network in the tumor 
site, and the close interactions between these cells pro-
foundly enhance tumor progression and metastasis [9]. The 
previous studies have determined that MDSC can induce 
 Foxp3+Treg [10]. On the other hand, Treg have the ability to 
promote the suppressive activity of MDSC, which represents 
the impact of cross interactions in tumor growth [11]. There-
fore, targeting both MDSC and Treg could be a promising 
approach to ablate the immunosuppressive network in the 
tumor microenvironment and provide enhanced anti-tumor 
immune responses.
Focusing on surface markers, numerous attempts have 
been employed to reduce the number of Treg [12–14]; how-
ever, these therapeutic strategies have been demonstrated to 
be only marginally successful [15]. An alternative approach 
involves targeting transcription factor Foxp3 due to its 
essential role in Treg suppressive function. The previous 
studies have reported that dendritic cells transfected with 
Foxp3 mRNA can induce CTL response against Foxp3 in 
melanoma-bearing mice [16]. Although this attractive 
strategy is robust and effective in depleting  Foxp3+Treg, 
elicitation of active and more comprehensive therapeutic 
approaches that target Treg through Foxp3 may provide 
more effective protection.
Over the past two decades, DNA vaccination has become 
a powerful immunotherapy to induce humoral and cellular 
immune responses against encoded antigens in tumor mod-
els [17, 18]. In addition, DNA vaccination has advantages 
over other cancer therapeutic approaches; it can induce the 
immune system against itself and weakly immunologic anti-
gens such as transcription factors by facilitating their MHC 
class I presentation [19, 20]. Therefore, we produced a DNA 
vaccine against Foxp3 that includes a plasmid-encoding 
truncated Foxp3 gene and Foxp3 recombinant protein in 
a prime-boost regimen. We have recently shown that our 
novel Foxp3 DNA/recombinant protein vaccine has the abil-
ity to reduce the accumulation of  CD4+Foxp3+Treg through 
the induction of CTL. This vaccine also potently induces 
humoral immune responses [21, 22]. In this regard, here, we 
reproduced our DNA vaccine, which is tested in the B16F10 
melanoma model to evaluate not only the accumulation of 
Treg but also to determine the effect of Treg depletion on 
the frequency and functions of MDSC and anti-tumor T-cell 
response.
Materials and methods
Construction of plasmids
The plasmid pSP73-Spf/Foxp3/A64 encoding Foxp3 mRNA 
without nuclear localization signal sequence was kindly pro-
vided by E. Gilboa (Miami, USA). The plasmid pEGFP-N1 
under control of cytomegalovirus promoter and the prokary-
otic expression vector pET24a+ carrying (poly)-histidine-
tagged (His-tag) sequence for protein detection and purifica-
tion (purchased from National Gene Bank, Pasteur Institute 
of Iran), both containing kanamycin resistance gene, were 
used as the backbone for the DNA vaccine. According to dis-
tinct plasmids for DNA and recombinant protein fractions, 
two pairs of primers were designed to obtain the sequence-
encoding truncated Foxp3 from pSP73-Spf/Foxp3/A64 plas-
mid using PCR. The PCR products using the Kozak/HindIII 
5′-TAT AAG CTT GCC ACC ATG GCT CCT TCC TTG GCC 
CT-3′ (forward) and KpnI 5′-CTT GGT ACC AGG GCG AAC 
ATG CGA GTA AAC-3′ (reverse) primers were inserted into 
the pEGFP-N1 plasmid using T4 DNA ligase to construct 
the Fox-GFP vector. Subsequently, the products using the 
EcoRI 5′-TAT GAA TTC GCT CCT TCC TTG GCC C-3′ (for-
ward) and XhoI 5′-CTT CTC GAG GGC GAA CAT GCG AG-3′ 
(reverse) primers were inserted into pET24a+ and ligated 
to generate Fox-pET expression plasmid. The Fox-GFP 
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and Fox-pET plasmids were transformed and amplified in 
DH5α and BL21 (DE3) competent Escherichia coli (E. coli), 
respectively, and then confirmed through kanamycin resist-
ance, colony PCR, and digestion with restriction enzymes. 
Finally, constructs were purified by Plasmid Mini Kit (Qia-
gen, Germany) and verified through DNA sequencing.
EndoFree plasmid purification for immunization
The constructed plasmid Fox-GFP and the plasmid pEGFP-
N1, as a control vector that was cloned into DH5α E. coli, 
were purified with EndoFree Plasmid Purification Giga Kit 
according to the manufacturer’s instructions (Qiagen). DNA 
concentration was determined using a Nanodrop analyzer 
(Thermo Fisher, USA).
Expression and purification of Foxp3 recombinant 
protein
The procedure for expression and purification of Foxp3 
recombinant protein in BL21-transformed Fox-pET cells 
was previously explained in detail [21]. To confirm Foxp3 
recombinant protein expression, SDS-PAGE was performed 
on BL21 E. coli transformed with the Fox-pET plasmid. 
The Foxp3-His-tag recombinant protein was purified using 
nickel–nitrilotriacetic acid (Ni–NTA) affinity chromatogra-
phy according to the manufacturer’s instructions (Qiagen, 
Germany). The samples of different steps of purification 
were analyzed using SDS-PAGE. Purified protein was dia-
lyzed using Slide-A-Lyzer dialysis cassette (10 K, Thermo 
Fisher, USA) for 48 h in PBS (pH 7.4), to prevent protein 
aggregation, and Western blot analysis was performed on 
dialyzed Foxp3-His-tag protein using anti-His-tag HRP-
conjugated antibody (Sigma, USA). The protein concentra-
tion was measured using Bicinchoninic Acid (BCA) Protein 
Assay Kit (Thermo Fisher).
Animals and tumor cell line
Five-week-old C57BL/6 female mice were purchased from 
Pasteur Institute (Tehran, Iran) and were housed under stand-
ard laboratory conditions in a temperature controlled and 
light-cycled facility.
Mouse melanoma cell line B16F10 was purchased from 
Cell Bank of Iran (Pasteur Institute, Tehran, Iran) and main-
tained in RPMI 1640 medium (R10, Gibco, USA) supple-
mented with 10% FBS (Gibco), 2 mM l-glutamine (Gibco), 
100 U/ml penicillin and 100 μg/ml streptomycin (Gibco) at 
37 °C under a humidified atmosphere of 5%  CO2.
The B16F10 lysate at  107 tumor cells/ml was prepared by 
repeated rounds of freezing in liquid nitrogen and thawing 
in a 37 °C water bath. The concentration of cell line lysate 
was measured using a BCA protein assay.
Prophylactic immunization
Mice were randomly assigned to Foxp3-vaccinated and con-
trol groups (n = 11 per group). For prophylactic vaccination, 
the vaccinated group mice were injected i.m. with 100 μg of 
Fox-GFP plasmid suspended in 100 μl of sterile PBS into 
the upper leg muscle on day 38 before tumor challenge. The 
control group mice were injected with 100 µg of pEGFP-N1, 
as the control vector. On day − 24, the vaccinated mice were 
injected i.d. into the loose skin over the neck with 20 µg 
of recombinant Foxp3 protein emulsified in incomplete 
Freund’s adjuvant (IFA, Sigma), as the primary injection. 
Two weeks later, these mice were given a boost injection 
with 20 µg of recombinant Foxp3 protein emulsified in IFA. 
The control group was given 20 µg of molecular grade BSA 
emulsified in IFA at each indicated timepoint. Three mice 
from each group were killed 1 week after the last immuniza-
tion to assess the effect of the vaccine on the frequency of 
 CD4+Foxp3+ T cells.
Tumor challenge
Ten days following the last immunization, both Foxp3-vac-
cinated and control groups were s.c. inoculated with 5 × 105 
B16F10 melanoma cell line (in 200 µl of RPMI medium) in 
the right flank. When the tumor was palpable, tumor area 
 (mm2) was measured every other day using digital calipers. 
The survival of tumor-bearing mice was monitored daily. 
Thirteen days after tumor challenge, three mice from each 
group were sacrificed and spleen and tumor tissues were 
used for further analysis.
Spleen and tumor tissue cell isolation
The cells from spleen and tumor tissues were isolated, as 
previously described [23]. Briefly, mechanically dissoci-
ated spleens were treated with RBC lysis buffer (0.15 mM 
NH4Cl, 10 mM KHCO3, 0.1 mM disodium EDTA, pH 7.2) 
and splenocytes were suspended in R10 media. Tumor tis-
sues were minced and then digested with 1 mg/ml of col-
lagenase IV and 500 µg/ml of DNase (Roche, Germany) 
at 37 °C for 30 min followed by passing through 50 μm 
nylon mesh. Dead cells were removed by centrifugation 
over Ficoll–Hypaque gradients (Lymphodex, InnoTrain, 
Germany).
Immunophenotyping by flow cytometry
The following antibodies and their relevant isotype controls 
were purchased from BioLegend (USA): Gr-1-APC (clone 
RB6-8C5), CD11b-PE (clone M1/70), CD4-APC (clone GK 
1.5), and Foxp3-Alexa Fluor 488 (clone MF-14). For cell 
surface staining, splenocytes and tumor cell suspensions 
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were first incubated with FcR blocker (Miltenyi Biotec, 
Germany) and then with the above-mentioned antibodies. 
For intracellular staining, cells were fixed and permeabilized 
using Foxp3 fix/perm buffer (BioLegend) following cell sur-
face staining. Cells were then incubated with anti-Foxp3 
antibody and analyzed using FACS Calibur flow cytometry 
(BD Biosciences).
Intracellular IFN‑γ assay
Splenic cells  (106/200 µl R10) were stimulated with or with-
out PMA (20 ng/ml, Sigma, USA) and ionomycin (2 µg/ml, 
Sigma, USA) in the presence of brefeldin (2 µl/ml, BioLeg-
end) and/or monensin (2 µl/ml, BioLegend) for 6 h at 37 °C. 
Cells were then harvested and stained for CD8-FITC surface 
marker followed by IFN-γ-APC intracellular staining after 
fixation with fix/perm solution (BioLegend). The expression 
levels of IFN-γ in  CD8+ T cells were assessed using FACS 
Calibur flow cytometry.
CD107a cytotoxicity assay
Splenocytes  (106/200 µl R10) were stimulated with 200 µg/
ml of B16F10 cell line lysate in the presence of CD107a-
APC antibody (BioLegend) and monensin (BioLegend) 
in 96-well round bottom culture plates at 37 °C for 6 h. 
Harvested cells were then surface stained with CD8-FITC 
antibody to detect the production of CD107a in CTL using 
FACS Calibur flow cytometry.
MDSC and ROS
The expression level of ROS in Gr-1+CD11b+ cells was 
measured, as previously described [23]. Briefly, tumor-
infiltrated immune cells and splenocytes suspended in PBS 
were incubated with 5 μM 2′, 7′-dichlorodihydrofluorescein 
diacetate (DCFDA, Sigma, USA) at 37 °C for 30 min. Cells 
were then labeled with Gr-1-APC and CD11b-PE, and the 
level of ROS in Gr-1+CD11b+ cells was detected using 
FACS Calibur flow cytometry.
Suppression assay
Gr-1+ cells were purified from splenocytes following the 
manufacturer’s instructions (Miltenyi Biotec). The suppres-
sion assay was performed, as previously described, with slight 
modification [23]. Briefly, nylon wool-purified naïve T cells 
 (105 cells/well) from a healthy adult C57BL/6 mouse were 
labeled with carboxy fluorescein succinimidyl ester (CFSE) 
and co-cultured with Gr-1+ cells (T cells/Gr-1+ cells = 2:1) 
(5 × 104 cells/well) from Foxp3-vaccinated or control mice 
in the presence of soluble anti-CD3 (1 μg/ml) and anti-CD28 
(5 μg/ml, Biolegend). Unstimulated and stimulated naïve T 
cells served as negative and positive controls  (Co− and  Co+), 
respectively. After 3 days, the supernatants were collected and 
the cells were harvested and stained with CD3-APC to analyze 
CFSE dilution using FACS Calibur flow cytometry. To assess 
the percentage of MDSC suppression, the proliferation index 
(PI) of samples was calculated by the following formula:
Nitrite production assay
The nitrite concentration in the co-culture supernatant was 
assessed by standard Griess reaction, as previously described 
[24].
RNA extraction and gene expression by real‑time PCR
Total RNA was extracted from splenocytes and tumor tissues 
using RNXplus (Sinaclon, Iran), according to the manufac-
turer’s instructions. Then, cDNA was synthesized using two-
step RT-PCR Kit (Vivantis, Malaysia). Real-time PCR was 
performed on Applied Biosystems Plus1 using Solis BioDyne 
5 × HOT FIREPOL EvaGreen qPCR Mix Plus (ROX, Esto-
nia), according to the manufacturer’s instructions using the fol-
lowing conditions: 95 °C for 15 min, and 95 °C for 15 s, 60 °C 
for 20 s, and 72 °C for 20 s for 40 cycles followed by 72 °C for 
10 min. The sequences of primers were as follows: Arg-1 (for-
ward) 5′-AAG AAA AGG CCG ATT CAC CT-3′; 5′-CAC CTC 
CTC TGC TGT CTT CC-3′ (reverse); iNOS (forward) 5′-AGT 
GGT GTT CTT TGC TTC -3′; 5′-GCT TGC CTT ATA CTG GTC 
-3′ (reverse); Foxp3 (forward) 5′-GCA GGG CAG CTA GGT 
ATC TGTAG-3′ 5′-TCG GAG ATC CCC TTT GTC TTATC-3′ 
(reverse); β-actin (forward) 5′TGG GCT TAC CTC ACT GCT 
TTC 3′, 5′TCA TCG CTA ATC ACG ACG CT 3′ (reverse). The 
level of mRNA in each sample was quantified using the  2−ΔΔct 
method.
Statistical analysis
Statistical analyses were performed using the GraphPad Prism 
6 software. Nonparametric means comparisons between two 
groups were conducted using Mann–Whitney U test. Survival 
data were analyzed by log-rank test. All flow cytometry data 
analyses were performed using the FlowJo software.
Results
Foxp3 DNA and recombinant protein generation
The Fox-GFP and Fox-pET vectors encoding function-
inactivated Foxp3 were constructed, as schematically 
% Suppression =
(PICo+ − PICo−) − (PITest − PICo−)
(PICo+ − PICo−)
× 100.
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shown in Fig. 1a, b, respectively. Colony PCR assays and 
restriction enzyme digestion followed by sequence anal-
ysis confirmed the construction of the vectors (data not 
shown).
To evaluate the expression of recombinant protein 
Foxp3, SDS-PAGE was performed using Fox-pET-trans-
formed BL21 E. coli cell lysates. The expression of the 
Foxp3 protein was detected as approximately 42  kDa 
(Fig. 1c). To confirm Foxp3 recombinant protein purifi-
cation, SDS-PAGE was performed using eluted fractions 
from different steps of Ni–NTA affinity chromatography 
(Fig. 1d). Finally, Western blot analysis was done on dia-
lyzed fractions of 2 and 3 purified from Ni–NTA using 
anti-His-tag antibody, where a clear band correspond-
ing to the molecular mass of Foxp3 recombinant protein 
(42 kDa) was detected (Fig. 1e).
Foxp3 vaccine consistently reduces  CD4+Foxp3+ Treg 
in B16F10 tumor
Transcription factor Foxp3 is the master regulator for sup-
pressive activities of Treg. Thus, targeting Foxp3 could be 
an alternative approach to mitigate the adverse effects of 
Treg in tumors. We have recently shown that prophylactic 
Foxp3 vaccine reduces Treg in splenocytes of tumor-free 
mice [21]. In this regard, we investigated whether this 
vaccine could also reduce the number of Treg in mela-
noma-bearing mice. To address this question, C57BL/6 
mice were immunized with Foxp3 DNA and recombinant 
protein in a protocol schematically indicated in Fig. 2a. 
We initially reassessed the impact of the Foxp3 vaccine 
on Treg before tumor challenge. Treg frequency was 
determined by  CD4+Foxp3+ lymphocytes in splenocytes 
and tumor samples using flow cytometry, as depicted in 
Fig. 2b. As expected, the Foxp3 vaccine reduced the fre-
quency of Treg in splenocytes of vaccinated mice 3 days 
before tumor challenge (Fig. 2c). We then investigated 
the impact of the Foxp3 vaccine on Treg in tumor condi-
tions and revealed a continuous reduction in the number 
of Treg 13 days after tumor challenge in comparison with 
control mice. Surprisingly, this reduction was more sig-
nificant in tumor-infiltrated immune cells than splenocytes 
(Fig. 2d). We also investigated the expression levels of 
Foxp3 gene by real-time PCR. In agreement with the flow 
cytometry data, we found a significant reduction in Foxp3 
gene expression in both the tumor site and splenocytes 
(Fig. 2e). Of note, we did not observe any adverse auto-
immune reactions such as vitiligo following vaccination. 
These data indicate that Foxp3 vaccination results in a 
consistent decrease in the frequency of  CD4+Foxp3+ Treg 
even in tumor-bearing mice.
Foxp3 vaccine reduces MDSC in melanoma‑bearing 
mice
The previous reports have revealed a close interaction 
between MDSC and Treg, thereby leading to the expan-
sion of Treg [10]. To investigate whether targeting Treg 
with the Foxp3 vaccine could impact the MDSC popula-
tions, the frequency of  Gr1+CD11b+ cells in splenocytes and 
tumor tissues 13 days after tumor challenge was measured. 
Remarkably, compared with control mice, we found a sig-
nificant decrease in the proportion of Gr-1+CD11b+ cells in 
the splenocytes of Foxp3-vaccinated mice (Fig. 3a). More 
importantly, this reduction was more significant in the tumor 
site (Fig. 3b). Therefore, targeting Treg, using Foxp3 vac-
cine, results in the simultaneous reduction of MDSC in the 
spleen and the tumor site of melanoma-bearing mice.
Foxp3 vaccine mitigates the suppressive activities 
of MDSC
We further evaluated the modulatory effects of the Foxp3 
vaccine on the suppressive properties of MDSC. To this 
end, the in vitro suppressing capacity of MDSC isolated 
from Foxp3 and control-vaccinated mice was assessed on 
stimulated naïve T cells. As depicted in Fig. 4a, b, MDSC 
isolated from Foxp3-vaccinated mice exhibited significantly 
less suppressive effects on stimulated T cells than control-
vaccinated mice. This reduction was also confirmed by the 
lower level of nitrite in the co-culture supernatants of the 
Foxp3-vaccinated group; however, the difference was not 
significant (Fig. 4c). Moreover, we observed that Foxp3 
vaccine reduced the production of ROS by MDSC obtained 
from either splenocytes or tumor tissues (Fig. 4d). Finally, 
we found that the gene expression levels of both iNOS 
(Fig. 4e) and Arg-1 (Fig. 4f) were significantly reduced 
in splenocytes and tumor tissues. Collectively, these data 
illustrate the ability of Foxp3 vaccination to modulate the 
suppressive functions of MDSC in melanoma conditions.
Foxp3 vaccine induces anti‑tumor T‑cell responses
We next investigated whether the Foxp3 vaccine could 
enhance anti-tumor T-cell response following depletion of 
these immunosuppressive cells. Therefore, the production 
levels of CD107a and intracellular expression of IFN-γ in 
 CD8+ T cells were measured in splenocytes. CD107a is the 
marker of lysosomal membrane and presented on the surface 
of cytotoxic T cells following perforin and granzyme secre-
tion. We observed that compared to the controls,  CD8+ T 
cells from Foxp3-vaccinated mice express higher levels of 
CD107a (Fig. 5a, b). Furthermore, we analyzed the anti-
tumor activity of CTLs by IFN-γ production. We found that 
compared to the control group, depletion of Treg, following 
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Fig. 1  Construction and generation of Foxp3 plasmids and recom-
binant protein. a, b Schematic representation of the construction of 
Fox-GFP and Fox-pET plasmids is shown, respectively. c SDS-PAGE 
analysis of an Foxp3 recombinant protein expressed in BL21 E. coli. 
M, protein marker; lanes 1 and 2, Fox-pET-transfected BL21 E. coli 
cells 3 h after IPTG induction; lane 3, Fox-pET-transfected BL21 E. 
coli cells before induction; lane 4, non-transfected BL21 E. coli cells. 
d SDS-PAGE analysis of various steps of Foxp3 recombinant protein 
purification using Ni–NTA resin. Lanes 1–4, final fraction elution of 
the column (pH 4.5) consists of Foxp3 recombinant protein; lane 5, 
flow through of the column at pH 6.3; lane 6, flow through of the col-
umn at pH 8; M, protein marker; lane 7, Fox-Pet-transfected BL21 E. 
coli lysate before Ni–NTA resin mixing; lane 8, transfected BL21 E. 
coli after IPTG induction; and lane 9, transfected BL21 E. coli before 
IPTG induction. e Western blot analysis of the pooled fraction 2 and 
3 elution (pH 4.5) from the Ni–NTA column (lane 1) and protein 
marker (M) represents the band at the molecular weight of approxi-
mately 40 kDa. IPTG isopropyl β d-thiogalactoside
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Foxp3 vaccination, results in enhanced IFN-γ production 
by  CD8+ T cells from the vaccinated group (Fig. 5c, d). 
Taken together, these data demonstrate that Foxp3 vaccine 
improves CTL responses in the melanoma model.
Vaccination against Foxp3 delays tumor growth 
and increases animal survival
Based on the enhanced CTL response, following Foxp3 
vaccination, we aimed to determine the effects of this 
vaccine regimen on tumor growth and survival rate. Inter-
estingly, compared to controls at day 16 after tumor chal-
lenge, we found a significant reduction in the tumor size 
in the Foxp3-vaccinated group (Fig. 6a). Although all 
the mice finally died, the survival of Foxp3-vaccinated 
mice was significantly increased compared to the controls 
(Fig. 6b). These data indicate that Foxp3 vaccination mod-
ulates the aggressive growth of melanoma in the animal 
model.
Fig. 2  Foxp3 vaccine reduces  CD4+Foxp3+ Treg. a Schematic rep-
resentation of vaccination and tumor challenge timeline. C57BL/6 
mice (n  =  11 per group) were immunized i.m. with pEGFP-N1 or 
Fox-GFP plasmids on day −  38. Mice were then injected i.d. with 
molecular grade bovine serum albumin or Foxp3 recombinant pro-
tein emulsified in IFA on days − 24 and − 10, as a prime-boost regi-
men. A week after the boost injection, mice (n = 3 per group) was 
sacrificed and examined for the frequency of  CD4+Foxp3+ T cells 
in splenocytes before tumor challenge. On day 0, B16F10 tumor cell 
line was injected s.c., and on day 13, the final analyses were assessed 
on spleens and tumors of mice (n  =  3 mice per group). b Repre-
sentative dot plots showing the frequency of  CD4+Foxp3+ T cells in 
splenocytes and cells isolated from tumor tissues. c Percentages of 
 CD4+Foxp3+ T cells in splenocytes before tumor challenge. d Per-
centages of  CD4+Foxp3+ T cells in spleen and tumor tissue obtained 
from Foxp3 vaccinated versus control mice 13 day post-tumor chal-
lenge. e Foxp3 gene expression in splenocytes and tumor tissues of 
Foxp3 vaccinated versus control mice 13  day post-tumor challenge 
(β-actin was used as housekeeping gene). Data represent mean ± one 
standard error of two independent experiments
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Discussion
Tumor stroma cells produce various mediators that recruit 
versatile immunosuppressive cells into the tumor micro-
environment. Treg and MDSC are recognized as the main 
tumor-infiltrating immunosuppressive cells and their consti-
tutive interactions generate an immunosuppressive network, 
thereby enhancing the tumor progression in a protected site 
[8, 25]. Therefore, identification of a feasible approach 
to target these cells may promote anti-tumor immune 
responses. Various groups have already demonstrated that 
targeting key Treg markers could overcome tumor immu-
nosuppression [13, 26, 27]. Among these markers, Foxp3 
is the most important marker expressed in the thymus dur-
ing central tolerance and plays an essential role in detection 
and function of Treg in the periphery [2, 28]. Moreover, it 
has been shown that Foxp3 can also be processed and pre-
sented as an endogenous antigen by MHC class I molecules, 
which finally leads to the induction of CTL [29]. It has been 
reported that some tumor cell lines also present this protein 
on their surfaces [30].
DNA vaccines have been introduced as one of the effec-
tive ways to enhance anti-tumor immune responses through 
cross presentation [18]. Our prophylactic DNA vaccine 
includes a plasmid-encoding truncated Foxp3 gene and 
Foxp3 recombinant protein emulsified in IFA in a prime-
boost regimen. This vaccine was supposedly processed via 
MHC class I and class II pathways to induce CTL via cross 
presentation.
Our group has recently reported the modulatory effects 
of the Foxp3 vaccine on the frequency of Treg in tumor-
free mice [21]. In the present study, we demonstrated that 
the prophylactic Foxp3 vaccine reduces accumulation of 
 CD4+Foxp3+Treg in both the periphery and the tumor 
microenvironment. Notably, we found that Foxp3 vaccine 
significantly influenced tumor recruiting than circulating 
Treg. Depleting the tumor-infiltrated Treg has shown to be 
an effective strategy to eradicate tumors and Foxp3 is a spe-
cific marker for tumor-infiltrating Treg [31, 32]. The previ-
ous studies using transgenic mice, in which the expression 
of diphtheria toxin receptor is under the control of Foxp3 
gene, have determined that targeting Foxp3 leads to deple-
tion of tumor-infiltrating Treg [33]. Furthermore, Larsen 
et al. described CTL in cutaneous T-cell lymphoma patients 
who were enhanced against Foxp3 antigen. Notably, most 
malignant T cells in this type of cancer are Treg, which 
express Foxp3 in the context of MHC class I and could be 
detected and killed by CTL [34]. Recently, it was reported 
that compared with wild-type B16F10 cell line, reduction 
of Foxp3 expression on B16F10 murine melanoma cell line 
using siRNA resulted in reduced  CD4+CD25+Foxp3+ Treg 
and improved tumor burden [35, 36]. Nair et al. have also 
shown that transfection of mice dendritic cells with Foxp3 
mRNA in melanoma model induces  CD8+ T cells against 
Foxp3 [16]. This group did not note any autoimmune dis-
ease, which is consistent with our observations. Thus, our 
results suggest that Foxp3 vaccine depletes mostly tumor-
infiltrating rather than naturally occurring Treg, which 
play an essential role in immune hemostasis. However, 
the mechanism(s) by which Foxp3 vaccine differentiates 
these two Treg populations are unknown and merits further 
investigation.
Apart from Treg, MDSC represent another major cell 
population involved in tumor progression. Induction of Treg 
has been recognized as one of the main immunosuppressive 
mechanisms mediated by MDSC [7, 10, 37]. On the other 
hand, recent studies have determined that Treg promote the 
suppressive activity of MDSC [11]. These studies demon-
strated a tight interaction between MDSC and Treg, thereby 
creating a network for tumor progression. The previous 
Fig. 3  Foxp3 vaccine reduces MDSC. The splenocytes and tumor 
cells from Foxp3-vaccinated or control mice 13 day post-tumor chal-
lenge were analyzed for Gr-1 and CD11b using flow cytometry (n = 6 
mice per group). a Representative dot plots indicating  Gr1+CD11b+ 
cells in Foxp3 vaccinated versus control mice. b Percentages of 
 Gr1+CD11b+ cells in splenocytes versus tumor cells. Data represent 
mean ± one standard error of two independent experiments
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reports have shown a reduction in Treg following depletion 
of MDSC, which emphasizes the crosstalk between these 
immunosuppressive cells [37]. Therefore, we investigated 
the effects of the Foxp3 vaccine on MDSC and found, for the 
first time, that our Foxp3 vaccine reduces the accumulation 
of both MDSC and Treg in both the spleen and the tumor 
site. Moreover, this reduction was more prominent in the 
tumor site than the periphery. These results coupled with 
the greater reduction of Treg in the tumor site provide com-
pelling evidence that the main target of our vaccine is the 
Fig. 4  Foxp3 vaccine strongly modulates the suppressive mecha-
nisms of MDSC.  Gr1+ cells isolated from splenocytes of Foxp3-
vaccinated or control mice 13  day post-tumor challenge and CFSE-
labeled naïve T cells isolated from splenocytes of healthy C57BL/6 
mice were co-cultured, as described in the “Materials and methods” 
(n = 6 mice per group). a Representative dot plots showing percent 
proliferation of CFSE-labeled T cells in the presence of MDSC iso-
lated from Foxp3-vaccinated versus control mice. b Percentages of 
splenocyte MDSC mediated suppression from Foxp3-vaccinated ver-
sus control mice. c Nitrite levels recovered from the supernatant of 
MDSC-T-cell co-culture. d MFI for ROS among  Gr1+CD11b+ cells 
in splenocytes and tumor-infiltrated cells obtained from Foxp3-vac-
cinated and control mice. e, f Expression of iNOS and Arg-1 genes 
in the splenocytes and tumor tissue of Foxp3-vaccinated versus con-
trol mice. β-actin was used as housekeeping gene. Data represent 
mean  ±  one standard error of two independent experiments. MFI 
mean fluorescence intensity
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microenvironment of the tumor where the immunoregula-
tory network exists.
MDSC have emerged as potentially important regulators 
of immune response with several immunosuppressive prop-
erties. MDSC can be differentiated from mature granulocyte 
and/or monocyte cells based on these immunosuppressive 
capabilities, which mediate anti-tumor immune response 
[38–40]. Although we were unable to investigate different 
subtypes of MDSC in this study, we have shown that our 
novel Foxp3 vaccine dampens the expression of ROS, Arg-1 
and iNOS as the most important suppressive functions of 
MDSC. Therefore, we speculate that Foxp3 vaccination 
results in reduced immunosuppressive activity of MDSC. 
It has been shown that MDSC have a function, as antigen-
presenting cells, at an early timepoint of the tumor challenge 
[41]. Therefore, there is a possibility that the Foxp3 vaccine 
might temporarily impact the suppressive capacity of MDSC 
by interaction with other antigen-presenting cells; however, 
Fig. 5  Foxp3 vaccine promotes CTL responses. Splenocytes from 
Foxp3-vaccinated and control mice were analyzed for CD107a and 
IFN-γ expression in  CD8+ T cells, as described in the “Materials and 
methods”. a Representative dot plots showing percent  CD8+CD107a+ 
T cells from the Foxp3-vaccinated and control mice. b Percentages 
of  CD8+CD107a+ T cells in Foxp3-vaccinated versus control mice. c 
Representative dot plots showing percentages of  CD8+ IFN-γ+ T cells 
from the Foxp3-vaccinated and control mice. d Percentages of  CD8+ 
IFN-γ+ T cells in Foxp3-vaccinated versus control mice (n = 6 mice 
per group). Data represent mean  ±  one standard error of two inde-
pendent experiments
Fig. 6  Foxp3 vaccine reduces 
the rate of tumor growth and 
enhances mice survival. a Rate 
of tumor growth reported in 
 mm2 is shown. b Kaplan–Meier 
curve represents the percentage 
of mice survival in each group 
(n = 5 mice per group). Data 
represent mean ± one standard 
error of two independent experi-
ments
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the cellular and molecular mechanisms underlying these 
effects remain to be determined.
The immunosuppressive Treg and MDSC mostly target 
CTL, as the essential players in anti-tumor immune response 
[40, 42]. We have previously shown the enhancement of 
Foxp3-specific cytotoxicity in vivo and in vitro in tumor-free 
mice [21]. Therefore, we assessed if depletion of Treg and 
MDSC could restore the cytotoxic function of tumor-specific 
 CD8+ T cells in a melanoma model. The expression of the 
glycoprotein CD107a was analyzed on splenocyte  CD8+ T 
cells to evaluate the cytotoxic activity, since this marker is 
expressed on the membrane of vesicles after perforin and 
granzyme exocytosis [43]. Our investigation revealed that 
when compared to the control vaccine, the cytotoxic activ-
ity of melanoma-specific  CD8+ T lymphocytes markedly 
enhanced in response to the Foxp3 vaccine. Furthermore, 
compared to controls, we found higher levels of IFN-γ in 
 CD8+ T lymphocytes from the Foxp3 vaccine-treated mice, 
which further confirmed the activation of CTL after deple-
tion of Treg and MDSC. This finding is in agreement with 
the previous studies that have shown that targeting tumor-
infiltrating Treg causes improved systemic CTL response 
and IFN-γ production in cancer models [32]. Regardless 
of some limitations in our studies, we demonstrated that 
the Foxp3 vaccine not only promotes Foxp3-specific CTL, 
as determined in our previous study, but also indirectly 
enhances tumor-specific CTL responses through reduction 
of both Treg and MDSC in the tumor microenvironment.
Depleting tumor-infiltrated Treg and MDSC along with 
increasing the cytotoxicity of tumor-specific T cells is likely 
to be essential in tumor immunotherapy. Here, we showed 
that although our Foxp3 vaccine did not induce complete 
eradication of the tumor, when compared to control animals, 
it drastically attenuated the tumor growth in accordance with 
longer survival of the Foxp3-vaccinated mice. Melanoma is 
one of the fastest growing tumors with a potent immuno-
suppressive microenvironment that is resistant to various 
conventional immunotherapies [44, 45]. There is a possibil-
ity that overcoming suppressive network using the Foxp3 
vaccine promotes the other suppressive mechanisms that 
potently support the melanoma growth. Although our data 
are encouraging, the therapeutic effects of our vaccine in 
other types of tumor models need to be evaluated. These 
studies will enable us to better understand the differences in 
the microenvironment of tumors, which could be the main 
obstacle for controlling complete tumor growth by the Foxp3 
vaccine.
In conclusion, we have provided critical evidence that 
Foxp3 DNA/recombinant protein vaccine can enhance the 
immune response in an animal model of melanoma by tar-
geting both Treg and MDSC. We suggest that this vaccine 
in combination with other immunotherapy approaches, such 
as a dendritic cell cancer vaccine, has the potential to inhibit 
tumor growth. Future studies are required to evaluate the 
capacity of the Foxp3 vaccine and validate targeting Foxp3 
for cancer treatment.
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